In one of two recently published studies in JAMA Neurology , Allie Seminer , MSc , and Alfredi Mulihano , undergraduate students in the School of Medicine at the University of Galway in Ireland, and colleagues found that GLP-1 receptor agonists significantly reduced the risk for all-cause dementia, but SGLT2 inhibitors did not
No matter how much medication you take, you'll get back to your original state after you quit the medication if you can't correct your lifestyle, Park said
Because IV infusions bypass both the digestive system and the muscle absorption step, they offer the most direct pathway for nutrient delivery available outside of emergency medical settings
One Phase 2 trial of lixisenatide in Parkinsons did meet its primary motor endpoint, the biology of GLP-1 in the brain is real, and questions remain about earlier intervention, specific subpopulations, and whether vascular or metabolic contributions to neurodegeneration might still respond